Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBITDA (2016 - 2025)

Historic EBITDA for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$39.6 million.

  • Ascendis Pharma A's EBITDA rose 144.02% to -$39.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$258.0 million, marking a year-over-year increase of 3693.64%. This contributed to the annual value of -$261.7 million for FY2025, which is 3504.33% up from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's EBITDA is -$39.6 million, which was up 144.02% from -$73.1 million recorded in Q3 2025.
  • Ascendis Pharma A's EBITDA's 5-year high stood at -$39.6 million during Q4 2025, with a 5-year trough of -$176.0 million in Q3 2023.
  • In the last 5 years, Ascendis Pharma A's EBITDA had a median value of -$113.3 million in 2024 and averaged -$110.0 million.
  • Per our database at Business Quant, Ascendis Pharma A's EBITDA plummeted by 46705.63% in 2021 and then soared by 6131.07% in 2025.
  • Over the past 5 years, Ascendis Pharma A's EBITDA (Quarter) stood at -$128.8 million in 2021, then decreased by 16.76% to -$150.4 million in 2022, then surged by 36.76% to -$95.1 million in 2023, then soared by 57.7% to -$40.2 million in 2024, then rose by 1.44% to -$39.6 million in 2025.
  • Its last three reported values are -$39.6 million in Q4 2025, -$73.1 million for Q3 2025, and -$45.6 million during Q2 2025.